Immunovant (IMVT) vs Krystal Biotech (KRYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Krystal Biotech (KRYS) has outperformed Immunovant (IMVT) over the past year, gaining 45.7% versus a gain of 40.6%. Over five years, KRYS leads with a +675.9% price change compared with +308.9% for IMVT. Krystal Biotech is the larger company by market cap ($9.15 billion vs $6.57 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMVT | KRYS |
|---|---|---|
| Share price | $31.77 | $308.89 |
| Market cap | $6.57B | $9.15B |
| 1-day change | -2.31% | -2.19% |
| YTD return | +24.98% | +25.29% |
| 1-year return | +40.64% | +45.69% |
| 5-year return | +308.88% | +675.91% |
| P/E ratio (TTM) | — | 41.97 |
| Forward P/E | — | 33.47 |
| EPS (TTM) | $-2.56 | $7.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $389.13M |
| Revenue growth (YoY) | — | +33.94% |
| Net income (latest FY) | $-505.61M | $204.83M |
| Operating margin | — | 41.45% |
| Net margin | — | 52.64% |
| 52-week high | $45.42 | $382.54 |
| 52-week low | $21.93 | $212.02 |
| Distance from 52-week high | -30.05% | -19.25% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +53.07% | +25.68% |
| Average volume | 1.42M | 283.88K |
| Shares outstanding | 206.95M | 29.63M |
| Employees | 315 | 295 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
IMVT vs KRYS FAQ
Which is bigger, Immunovant or Krystal Biotech?
Krystal Biotech (KRYS) is larger, with a market capitalization of $9.15B compared with $6.57B for Immunovant (IMVT).
Which stock has performed better over the past year, IMVT or KRYS?
KRYS returned +45.69% over the past 12 months, compared with +40.64% for IMVT (price return, excluding dividends). Past performance does not predict future results.
Are Immunovant and Krystal Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.